MaRS Innovation

Johnson & Johnson Innovation inks 17 collaborations

Friday, June 12, 2015

Johnson & Johnson Innovation has announced 17 new collaborations with research institutions and healthcare companies, bringing the total number of collaborations formed since the 2013 launch of Johnson & Johnson Innovation to more than 200. Johnson & Johnson Innovation seeks to identify and advance scientific innovation across the Johnson & Johnson segments of Pharmaceutical, Medical Devices and Consumer businesses.

[Read More]

Johnson & Johnson Innovation in Canadian collaboration

Wednesday, December 11, 2013

Johnson & Johnson Innovation is collaborating with two Canadian early-stage drug technology development centers to identify and advance biopharmaceutical technologies: Montreal-based NEOMED, a nonprofit, public-private pharma alliance dedicated to drug discovery and development; and Toronto-based MaRS Innovation, the commercialization agent for Ontario’s discovery pipeline from 16 academic institutions,

[Read More]

MaRS Innovation, GlaxoSmithKline partner to accelerate translational research

Tuesday, May 31, 2011

MaRS Innovation (MI) and GlaxoSmithKline (GSK) have announced a new development fund—the GSK-MaRS Innovation Fund—to support and fast-track the commercialization of some of Canada’s most promising translational research coming from 16 leading academic health sciences centers, hospitals and universities derived from the MI membership.

[Read More]